HAWTHORNE, N.Y., Sept. 25 (UPI) -- U.S. firm Acorda Therapeutics said Monday it has seen positive results from a phase 3 study of Fampridine-SR for mulitple sclerosis (MS).
CAMBRIDGE, Mass., Sept. 20 (UPI) -- U.S. firms Biogen Idec and Alnylam said Wednesday they have signed a deal on a drug for progressive multifocal leukoencephalopathy.
HAWTHORNE, N.Y., March 3 (UPI) -- Acorda Therapeutics said Friday it has completed enrollment in its phase 3 study of multiple sclerosis drug Fampridine SR.
CAMBRIDGE, N.Y., Feb. 15 (UPI) -- Biogen Idec and Elan said Wednesday they are OK'd to resume study of multiple sclerosis drug Tysabri.
BOSTON, Sept. 9 (UPI) -- Boston's struggling Biogen Idec Inc. will lay off 650 workers globally, sell a California plant and drop an underperforming psoriasis drug.
NEW YORK, Aug. 29 (UPI) -- A stock analyst has uncovered information suggesting that a recently withdrawn multiple sclerosis drug suppresses the immune system.
CAMBRIDGE, Mass., June 3 (UPI) -- Doctors say it is unlikely sales of a multiple sclerosis drug can resume if it is confirmed a fourth patient developed a brain infection after taking it.
CAMBRIDGE, Mass., March 31 (UPI) -- Biogen Idec Inc. of Boston and its Irish partner revealed Thursday a third person who got a rare but deadly brain disease after taking Tysabri.
CAMBRIDGE, Mass., Feb. 28 (UPI) -- Drug makers Biogen Idec of Cambridge, Mass., and Britain's Elan Monday suspended sales of their multiple sclerosis drug after one user died.
BOSTON, June 24 (UPI) -- Biogen and Idec Pharmaceuticals agreed to merge in a $6 billion stock swap that would create the country's third-largest biotech company.
